O ne of the major drives in cancer therapy in the last 40 years has been the development of drugs that are capable of killing tumor cells. Many of these drugs are DNA-damaging agents that exert their effects via interference with the DNA replicative machinery, either directly or by the production of damage that prevents efficient cell division. As a result, tumor cells (which often have a higher proliferative index than surrounding normal tissue) can prove sensitive to such agents. Unfortunately, a number of normal tissues, particularly those with a high proliferative potential, such as tissues of the lung, gut, and hemopoietic system, also exhibit sensitivity to antitumoral agents. This leads to collateral toxicity in patients undergoing chemotherapy and, if the toxicity becomes too severe, can result in limitation of chemotherapeutic dose and in inadequate tumor kill. Often this problem of the inherent sensitivity of normal cells is exacerbated by the development of drug resistance in malignant cells, a situation which may leave normal tissues more sensitive to cytotoxicity than the tumor.
These problems are exemplified by the O 6 -alkylating agents. This family of drugs, which includes the nitrosoureas and related methylating agents, are distinguished by their ability to cause alkylation at the O 6 position of guanine in DNA. In turn, O 6 -alkylguanine (O 6 -alkG) appears to be the predominant cytotoxic as well as mutagenic and carcinogenic lesion produced by these agents. The clinical use of O 6 -alkylating agents is associated with acute toxicities in the bone marrow (BM), lung, and gut, with chronic lung toxicity, and with the induction of iatrogenic leukemias. [1] [2] [3] [4] During its development in the mid 1980s, the imidazotriazene mitozolomide showed significant antitumoral activity in preclinical murine models. [5] [6] [7] After phase I clinical trials, the primary dose-limiting activity was determined to be thrombocytopenia, with evidence of dose-related, but not severe, gut toxicity. 8, 9 However, on progression to phase II trials, it became clear that although activity was seen in melanoma and small cell carcinoma of the lung, the unpredictable and often severe myelosuppressive effects associated with treatment were unacceptable. 10 -14 At this stage of development, mitozolomide was discontinued as a potential antitumoral agent.
Resistance to O 6 -alkylating agents is largely mediated by the DNA repair protein O 6 -alkG-DNA alkyltransferase (ATase), which transfers O 6 -alkG to its active center in a stochiometric and autoinactivating manner. [15] [16] [17] Expression of this protein in tumor cells correlates with their resistance to killing by O 6 -alkylating agents. 18, 19 Conversely, the extreme sensitivity of BM progenitors to such agents is a result of their low (often undetectable) levels of ATase. 20 Attempts to improve the therapeutic efficacy of the O 6 -alkylating agents have centered on circumventing ATase-mediated tumor cell resistance. To this end, the use of analogs of O 6 -alkG, such as O 6 -benzylguanine (O 6 -beG), has been demonstrated to lead to tumor sensitization if used in combination with O 6 -alkylating agent therapy. [21] [22] [23] [24] [25] However, a major impediment of this strategy may be the lack of tumor specificity of O 6 -beG, because a number of studies have shown that this approach also leads to increased killing of normal tissues. 20,26 -28 The discovery and development of various mutant forms of ATase that exhibit different levels of resistance to inactivation by O 6 -beG 29, 30 has led to the possibility of developing a gene therapy strategy in which tumor sensitization might be combined with normal tissue protection to increase the therapeutic index. [31] [32] [33] [34] [35] We have been investigating the utility of a double-mutated form of ATase (hATPA/GA) in providing O 6 -beG-insensitive protection against O 6 -alkylating agent toxicity and clastogenicity. [32] [33] [34] [35] Here we report the effects of retroviral expression of this mutated repair protein in hemopoietic cells on the in vivo biological effects of mitozolomide and discuss the implications that the clinical use of this protective strategy, together with an otherwise proscribed drug, may have for cancer treatment.
MATERIALS AND METHODS

Materials
Mitozolomide was obtained from May-Baker (Dagenham, UK). It was dissolved in dimethylsulfoxide (100 mg/mL) and appropriately diluted in phosphate-buffered saline for intraperitoneal (i.p.) injection into mice. O 6 -beG was a generous gift from Dr. R. S. McElhinney and Prof. B. McMurry (Trinity College, Dublin, Ireland) and was homogeneously suspended in corn oil using a Teflon glass homogenizer (Scientific Laboratory Supplies, Nottingham, UK) for i.p. injection into mice. 5-fluorouracil (250 mg/mL solution) was purchased from David Bull Laboratories (Warwick, UK). Recombinant human interleukin-6 (IL-6) was obtained from Sandoz (Basel, Switzerland), recombinant murine IL-3 was obtained from R&D systems (Abingdon, UK), and recombinant rat stem cell factor was obtained from Amgen (Thousand Oaks, Calif).
Producer cells
The LhATPA/GA vector that expresses the human hATPA/GA protein was constructed by cloning the hATPA/GA cDNA 32 into the retroviral vector pLX derived from the LN series of vectors. 36 After derivation of ecotropic packaging cells producing LhATPA/GA vector, these cells were cocultured with amphotropic GP ϩ envAM12 cells in a "ping-pong" method to increase the viral titer. Amphotropic producer cells were then selected by culturing in the presence of 200 g/mL hygromycin for 7 days, and the resulting cultures produced virus with a titer of in excess of 5 ϫ 10 5 infectious particles/mL.
Animal studies B6D2F 1 male donor mice (9 -12 weeks of age) were treated with 150 mg/kg 5-fluorouracil by intravenous injection. After 2 days, BM cells were harvested from the femurs and cultured for 2 days at 37°C in Dulbecco's modified Eagle's medium supplemented with 20% fetal calf sera, 0.1% bovine serum albumin, 2 mM glutamine, 10 ng/mL recombinant murine IL-3, 100 ng/mL recombinant rat stem cell factor, and 200 U/mL recombinant human IL-6. The BM cells were scraped from the culture flasks and overlayed on either GP ϩ envAM12 (mock) or LhATPA/GA retroviral producer cells for 2 days in the same medium with the addition of 4 g/mL polybrene. Supernatant cells were then collected, washed, and used either for transplantation into 8-to 10-week-old, BM-ablated (15.2 Gy, Cobalt 60 source for 16 hours) female B6D2F 1 mice (5 ϫ 10 6 cells per mouse) or for granulocyte-macrophage colony-forming cell (GM-CFC) colony plating in methylcellulose and cytospin preparation.
To assess the gene transduction frequency among spleen colony-forming units (CFU-S), 10 recipient mice were transplanted with 1 ϫ 10 6 cells each. The mice were sacrificed 12 days later and either spleens were fixed in 70% ethanol for immunocytochemical analysis or individual spleen colonies were carefully dissected out for DNA isolation and subsequent polymerase chain reaction (PCR) analysis.
At 1 month posttransplantation, groups of five mice were treated with mitozolomide (1 mg/kg i.p.) either alone or 2 hours after receiving a single dose of O 6 -beG (30 mg/kg i.p). After 24 hours, the treated mice were sacrificed by cervical dislocation, and femoral BM cells were harvested and used for CFU-S and GM-CFC analysis as described previously. 28 
PCR analysis
PCR analyses were carried out on individual GM-CFC colonies picked from methylcellulose and on DNA isolated from day 12 spleen colonies. A PCR product of 624 bp corresponding to the hAT cDNA was amplified by 30 rounds of PCR using the primers 5Ј-ATGGACAAGGATTGTGAAATGAAACG-3Ј and 5Ј-TCAGTTTCGGCCAGCAGGCGG-3Ј. Detection of male (donor) cells in the female recipients was performed by PCR using the primers 5Ј-AAGCGCCCCATGAATGCATT-3Ј and 5Ј-TCCCAGCTGCTTGCTGATCT-3Ј to amplify a 105-bp fragment of the murine Y chromosome-specific Sry gene. 37 
Immunocytochemistry
Day 12 spleen colonies (3-m sections) and cytospin preparations of transduced BM cells were stained with a rabbit polyclonal antibody specific for human ATase using a streptavidin biotin peroxidase complex detection system (Vector Laboratories, Peterborough, UK).
Micronucleus test
Four control and seven LhATPA/GA-transduced mice were treated with a single dose of mitozolomide (0.5 mg/kg i.p) 2 hours after administration of O 6 -beG (30 mg/kg i.p) in corn oil. The treated mice were sacrificed 24 hours later, and femoral marrow cells were flushed into fetal calf sera. BM smears were prepared from the cell pellets, fixed in methanol for 10 minutes, and subsequently stained with acridine orange. The slides were scored independently by two separate investigators for micronucleated polychromatic erythrocytes (MPCE) among 2000 polychromatic erythrocytes (PCE); results were expressed as MPCE per 1000 PCE.
Statistical analysis
The unpaired Student's t test was used to compare the difference between experimental groups.
RESULTS
Transduction of BM
After in vitro transduction of murine BM with the LhATPA/GA vector, the cells were harvested and used to reconstitute potentially lethally irradiated mice. Using PCR analysis, it was established that 50% of BM GM-CFC and CFU-S contained the transgene (data not shown). Immunohistochemical analysis of spleen colonies and BM showed that ATase was also expressed in ϳ50% of these cells, in close agreement with the PCR data. Furthermore, ATase protein was localized to the nucleus of transduced cells (Fig 1) .
Sensitivity of BM in vivo to mitozolomideinduced toxicity
To test the sensitivity of control and transduced BM to killing by mitozolomide, mice were challenged with mitozolomide alone (1 mg/kg) or with O 6 -beG (30 mg/kg) 2 hours before administration of mitozolomide (1 mg/kg). Mice were sacrificed after 24 hours, and BM was taken for quantitation of GM-CFC (Fig 2) and CFU-S (Fig 3) . Cells from control (untransduced) animals were extremely sensitive in vivo to the cytotoxic effects of mitozolomide. Thus, GM-CFC levels were reduced to 70% of those in untreated mice by administration of mitozolomide alone, and to 24% of control levels by the combination of O 6 -beG and mitozolomide. Similarly, CFU-S levels were reduced to 62% and 18% of those in untreated mice after challenge with mitozolomide or O 6 -beG/mitozolomide respectively. In contrast, however, the BM of mice that had been reconstituted with hATPA/GA-transduced cells exhibited substantial resistance to the cytotoxic effects of mitozolomide. Thus, in the absence of O 6 -beG pretreatment, no significant toxicity was seen in either the GM-CFC or CFU-S compartments. After pretreatment with O 6 -beG, both the GM-CFC and CFU-S populations exhibited a 2-fold increased survival over their counterparts from untransduced mice (44% survival of GM-CFC, P Ͻ .05 compared with untransduced controls; 37% survival of CFU-S, P Ͻ .01 compared with untransduced mice).
Sensitivity of BM to mitozolomideinduced clastogenicity
To assess the effects of hATPA/GA transduction on the clastogenicity of mitozolomide in vivo, we used the mouse BM micronucleus assay (Fig 4) . When BM from either untransduced or hATPA/GA-transduced mice was assessed in the absence of drug treatment, low levels of MPCE were seen; these levels did not vary between the two groups, indicating that the transduction/transplantation protocol had no effect on the background micronucleus frequency. However, when untransduced mice were exposed to mitozolomide (0.5 mg/kg) 2 hours after pretreatment with O 6 -beG, a 5-fold increase in the frequency of MPCE was observed (from 4 to 21 MPCE per 1000 PCE). In contrast, when hATPA/GA mice were treated with the O 6 -beG/mitozolomide combination, the frequency of micronucleus induction was significantly reduced compared with that seen in untransduced controls treated similarly (P ϭ .015).
DISCUSSION
In a number of preclinical studies, mitozolomide showed promising antitumoral activity. [5] [6] [7] Phase I clinical trials identified a recommended oral dose of 115 mg/m 2 for future investigations, with myelosuppression as the doselimiting collateral toxicity. 8, 9 However, phase II trials quickly showed evidence of unpredictable and unacceptable myelotoxicity, particularly thrombocytopenia, with only marginal effects against tumors at the doses used (reduced to 90 mg/m 2 to limit side effects). 10 -14 Given these effects, the use of mitozolomide in chemotherapy was discontinued. Aside from the myelosuppressive effects of mitozolomide, one encouraging aspect of the clinical trials was the lack of other serious side effects of this agent. Indeed, in one trial in which BM support was used to facilitate dose escalation, doses of up to 400 mg/m 2 were given, with the only significant toxicity being thrombocytopenia. 38 Thus, it would seem that, given proper protection of the hemopoietic compartment, it may prove possible to escalate mitozolomide doses to clinically effective levels without undue adverse effects on other tissues.
A number of genes have been identified that, when expressed in otherwise drug-sensitive tissues, can confer protection against various cytotoxic agents; in addition, a number of these genes have been expressed in BM 39 -42 with a view toward providing chemoprotection in a clinical context. The sensitivity of cells to the cytotoxicity and other biological effects of the O 6 -alkylating agents is generally a function of the levels of the repair protein ATase. In general, cells expressing high levels of ATase are resistant to O 6 -alkylating agents, 18, 19, [43] [44] [45] whereas those (such as human hemopoietic cells) that have low levels are extremely sensitive. 20, 46 This situation is magnified by the fact that repair inactivates the ATase protein; thus, there is a very strict correlation between the levels of ATase and drug sensitivity. Indeed, downmodulation of ATase levels via the use of O 6 -beG can be used as a means of sensitizing otherwise resistant tumors to killing by O 6 -alkylating agents. 21, [23] [24] [25] 47 However, the effects of O 6 -beG are not restricted to tumor tissue, and the use of this inactivator before treatment with O 6 -alkylating agents also results in toxicity to normal cells, including those of the hemopoietic system. 20,26 -28 Thus, a strategy has emerged whereby it may prove possible to enhance the therapeutic effects of the O 6 -alkylating agents; this strategy incorporates the use of potentially powerful tumor sensitizers such as O 6 -beG. Mutant forms of ATase have been characterized that exhibit resistance to inactivation by O 6 -beG while retaining the ability to repair O 6 -alkG in DNA. 29, 30 We have been working with a double-mutated form of human ATase, hATPA/GA, and have shown previously that it can confer O 6 -beG-insensitive protection against the cytotoxic effects of the methylating agent temozolomide, one of the compounds that has replaced mitozolomide in the clinic. [32] [33] [34] Here we show that retrovirus-mediated gene transfer and expression of hATPA/GA in mouse BM leads to substantial, multilineage protection against mitozolomide-induced cytotoxicity. Thus, after just a single round of challenge with mitozolomide, a 2-fold increased survival was seen in both the GM-CFC and CFU-S populations. Furthermore, this protective effect was maintained when mice were administered mitozolomide in combination with the ATase inactivator O 6 -beG. Similarly, mice that were engrafted with hATPA/GAtransduced BM showed a much reduced frequency of micronucleus induction in the erythroid compartment compared with mock-transduced controls. Thus, we have demonstrated protective effects of hATPA/GA in two mature compartments (granulocyte-macrophage and erythroid) and one primitive compartment (CFU-S) of the hemopoietic tissue. This multilineage in vivo protection against mitozolomide toxicity under circumstances in which substantial sensitization of tumors might be expected suggests that it may prove possible to administer this agent in a therapeutically effective manner and dose, without undue myelosuppressive effects, provided that the patient has been engrafted previously with autologous hATPA/GA-transduced hemopoietic cells. Moreover, the reduced frequency of micronucleus (and by inference mutation) induction in the protected BM would imply that the risk of longer-term effects of mitozolomide treatment, such as secondary leukemias, will also be reduced.
Gene therapy clinical trials of ATase-mediated chemoprotection will soon be undertaken. These will focus initially on the potential for protection against agents such as 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea. Given the effects of such drugs on tissues other than BM, it is unclear as to what window of opportunity for dose escalation will be presented to the clinician before the next normal tissue toxicity leads to limitations in treatment. For example, with BCNU, acute lung toxicity may be expected to present problems that will not be ameliorated by ATase expression in the BM.
1,2 Moreover, no protection against the longer-term nonhemopoietic effects (e.g., lung fibrosis) of such agents will be provided. 3, 4 One advantage in reconsidering mitozolomide is that this agent has not been associated with any significant nonhemopoietic toxicities in clinical trials, and so may be particularly suited for use in conjunction with chemoprotective gene transfer. An additional advantage, especially in relation to temozolomide, may lie in the way chloroethylating agents such as mitozolomide kill cells. The mode of toxicity of this class of agent is likely to be via the generation of interstrand DNA cross-links produced by the reaction of the cyclic intermediate N-1-O 6 -ethanoguanine with the cytosine residue of the opposite strand. As this would block DNA replication, it is likely to be fatal for the cell. The half-life of O 6 -chloroethylguanine adducts is ϳ6 hours; after this time, they are not likely to be repaired by ATase. The mechanism of cell killing by methylating agents such as temozolomide is somewhat more obscure. One possibility is that the O 6 -methylguanine (O 6 -meG):thymine mispair generated as a result of a round of DNA replication may be a substrate for mismatch repair proteins. This may result in the cleavage of the newly synthesized strand and removal of the thymine residue. However, during subsequent repair synthesis, the O 6 -meG adduct will again miscode, and the mismatch repair substrate will be regenerated and recleaved, thereby resulting in an effectively permanent and potentially lethal strand break. More recently, it has also been shown that O 6 -meG can block DNA polymerase in vitro. 48 If this occurs in vivo, it may also represent a major mode of toxicity for these agents. However, both mechanisms of methylating agent cytotoxicity require DNA replication; thus, lesions may persist in DNA for perhaps up to 36 hours before exerting any biological effect. Thus, the toxicity associated with methylating agents may be com-promised somewhat by de novo resynthesis of ATase after depletion by O 6 -beG. The more rapid conversion of O 6 -chloroethylguanine to a toxic intermediate may be less affected by the resynthesis rate. Certainly, this has been the case for the chloroethylating agent BCNU, which has proved more toxic than temozolomide when administered to mice in combination with O 6 -beG. 28 If collateral damage in tissues other than the BM were to prove less of a problem with mitozolomide than with BCNU, it may be possible to achieve increased tumor kill without undue side effects in other tissues. However, it will clearly be important to establish experimentally whether mitozolomide has advantages over either temozolomide or BCNU when used with O 6 -beG in combination with BM protection. This will necessitate an evaluation not only of the protection of primitive hemopoietic cells but also of the impact of protection on the mature blood cell populations as well as effects in other potentially sensitive normal tissues. If successful, this approach could prove to be a paradigm for the reintroduction to clinical practice of otherwise proscribed myelotoxic drug combinations.
